Abstract
Parkinson's disease (PD) is a neurodegenerative disorder affecting a significant proportion of the ageing population. The etiology is unknown and it is likely due to a multifactorial interaction of genes and the environment on the background of ageing. Findings in the last decade suggest that the contribution of genetics to familial forms of PD is much greater than previously appreciated. Twelve loci are now associated with highly penetrant autosomal dominant or recessive PD, and causative mutations have been identified in eight genes with mutation carriers often characterized by a phenotype indistinguishable from idiopathic disease. To date, PD pharmacotherapy is symptomatic only and does not slow disease progression. Understanding how genetic mutations cause familial PD is likely to clarify molecular mechanisms underlying PD in general and will provide a guide for the development of novel therapies, both preventative and palliative, applicable to all forms of parkinsonism. This review outlines the advances in the study of the genetic background of PD and their possible clinical implications.
Similar content being viewed by others
Article PDF
References
de Rijk MC, Launer LJ, Berger K, Breteler MM, Dartigues JF, Baldereschi M, et al. Prevalence of Parkinson's disease in Europe: A collaborative study of population-based cohorts. Neurologic Diseases in the Elderly Research Group. Neurology 2000; 54: S21–3.
Fahn S . Description of Parkinson's disease as a clinical syndrome. Ann N Y Acad Sci 2003; 991: 1–14.
Forno LS . Neuropathology of Parkinson's disease. J Neuropathol Exp Neurol 1996; 55: 259–72.
Nussbaum RL, Polymeropoulos MH . Genetics of Parkinson's disease. Hum Mol Genet 1997; 6: 1687–91.
Dauer W, Przedborski S . Parkinson's disease: mechanisms and models. Neuron 2003; 39: 889–909.
Dawson TM, Dawson VL . Molecular pathways of neurodegeneration in Parkinson's disease. Science 2003; 302: 819–22.
Cookson MR . The biochemistry of Parkinson's disease. Annu Rev Biochem 2005; 74: 29–52.
Leroux PD . Contribution à l'étude des causes de la paralysie agitante. in Thesis. 1880: Paris.
Gowers WR . A Manual of Diseases of the Nervous System. Vol 1. Philadelphia: Blakiston's Son; 1900.
Lang AE, Lozano AM . Parkinson's disease. First of two parts. N Engl J Med 1998; 339: 1044–53.
Rocca WA, McDonnell SK, Strain KJ, Bower JH, Ahlskog JE, Elbaz A, et al. Familial aggregation of Parkinson's disease: The Mayo Clinic family study. Ann Neurol 2004; 56: 495–502.
Tanner CM, Ottman R, Goldman SM, Ellenberg J, Chan P, Mayeux R, et al. Parkinson disease in twins: an etiologic study. JAMA 1999; 281: 341–6.
Wirdefeldt K, Gatz M, Schalling M, Pedersen NL . No evidence for heritability of Parkinson disease in Swedish twins. Neurology 2004; 63: 305–11.
Piccini P, Burn DJ, Ceravolo R, Maraganore D, Brooks DJ . The role of inheritance in sporadic Parkinson's disease: evidence from a longitudinal study of dopaminergic function in twins. Ann Neurol 1999; 45: 577–82.
Maher NE, Currie LJ, Lazzarini AM, Wilk JB, Taylor CA, Saint-Hilaire MH, et al. Segregation analysis of Parkinson disease revealing evidence for a major causative gene. Am J Med Genet 2002; 109: 191–7.
Farrer MJ . Genetics of Parkinson disease: paradigm shifts and future prospects. Nat Rev Genet 2006; 7: 306–18.
Tan EK, Skipper LM . Pathogenic mutations in Parkinson disease. Hum Mutat 2007; 28: 641–53.
Polymeropoulos MH, Lavedan C, Leroy E, Ide SE, Dehejia A, Dutra A, et al. Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science 1997; 276: 2045–7.
Singleton AB, Farrer M, Johnson J, Singleton A, Hague S, Kachergus J, et al. alpha-Synuclein locus triplication causes Parkinson's disease. Science 2003; 302: 841.
Leroy E, Boyer R, Auburger G, Leube B, Ulm G, Mezey E, et al. The ubiquitin pathway in Parkinson's disease. Nature 1998; 395: 451–2.
Paisan-Ruiz C, Jain S, Evans EW, Gilks WP, Simon J, van der Brug M, et al. Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease. Neuron 2004; 44: 595–600.
Zimprich A, Biskup S, Leitner P, Lichtner P, Farrer M, Lincoln S, et al. Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. Neuron 2004; 44: 601–7.
Kruger R, Kuhn W, Muller T, Woitalla D, Graeber M, Kosel S, et al. Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease. Nat Genet 1998; 18: 106–8.
Zarranz JJ, Alegre J, Gomez-Esteban JC, Lezcano E, Ros R, Ampuero I, et al. The new mutation, E46K, of alpha-synuclein causes Parkinson and Lewy body dementia. Ann Neurol 2004; 55: 164–73.
Maraganore DM, de Andrade M, Elbaz A, Farrer MJ, Ioannidis JP, Kruger R, et al. Collaborative analysis of alpha-synuclein gene promoter variability and Parkinson disease. JAMA 2006; 296: 661–70.
Ibanez P, Bonnet AM, Debarges B, Lohmann E, Tison F, Pollak P, et al. Causal relation between alpha-synuclein gene duplication and familial Parkinson's disease. Lancet 2004; 364: 1169–71.
Farrer M, Maraganore DM, Lockhart P, Singleton A, Lesnick TG, de Andrade M, et al. alpha-Synuclein gene haplotypes are associated with Parkinson's disease. Hum Mol Genet 2001; 10: 1847–51.
Pals P, Lincoln S, Manning J, Heckman M, Skipper L, Hulihan M, et al. alpha-Synuclein promoter confers susceptibility to Parkinson's disease. Ann Neurol 2004; 56: 591–5.
Lorincz MT . Clinical implications of Parkinson's disease genetics. Semin Neurol 2006; 26: 492–8.
Spillantini MG, Schmidt ML, Lee VM, Trojanowski JQ, Jakes R, Goedert M . Alpha-synuclein in Lewy bodies. Nature 1997; 388: 839–40.
Gosal D, Ross OA, Toft M . Parkinson's disease: the genetics of a heterogeneous disorder. Eur J Neurol 2006; 13: 616–27.
Maraganore DM, Lesnick TG, Elbaz A, Chartier-Harlin MC, Gasser T, Kruger R, et al. UCHL1 is a Parkinson's disease susceptibility gene. Ann Neurol 2004; 55: 512–21.
Lowe J, McDermott H, Landon M, Mayer RJ, Wilkinson KD . Ubiquitin carboxyl-terminal hydrolase (PGP 9.5) is selectively present in ubiquitinated inclusion bodies characteristic of human neurodegenerative diseases. J Pathol 1990; 161: 153–60.
Pickart CM . Ubiquitin in chains. Trends Biochem Sci 2000; 25: 544–8.
Funayama M, Hasegawa K, Kowa H, Saito M, Tsuji S, Obata F . A new locus for Parkinson's disease (PARK8) maps to chromosome 12p11.2-q13.1. Ann Neurol 2002; 51: 296–301.
Funayama M, Hasegawa K, Ohta E, Kawashima N, Komiyama M, Kowa H, et al. An LRRK2 mutation as a cause for the parkinsonism in the original PARK8 family. Ann Neurol 2005; 57: 918–21.
Gilks WP, Abou-Sleiman PM, Gandhi S, Jain S, Singleton A, Lees AJ, et al. A common LRRK2 mutation in idiopathic Parkinson's disease. Lancet 2005; 365: 415–6.
Kachergus J, Mata IF, Hulihan M, Taylor JP, Lincoln S, Aasly J, et al. Identification of a novel LRRK2 mutation linked to autosomal dominant parkinsonism: evidence of a common founder across European populations. Am J Hum Genet 2005; 76: 672–80.
Gasser T . Genetics of Parkinson's disease. Curr Opin Neurol 2005; 18: 363–9.
Mata IF, Kachergus JM, Taylor JP, Lincoln S, Aasly J, Lynch T, et al. Lrrk2 pathogenic substitutions in Parkinson's disease. Neurogenetics 2005; 6: 171–7.
Mata IF, Wedemeyer WJ, Farrer MJ, Taylor JP, Gallo KA . LRRK2 in Parkinson's disease: protein domains and functional insights. Trends Neurosci 2006; 29: 286–93.
Ozelius LJ, Senthil G, Saunders-Pullman R, Ohmann E, Deligtisch A, Tagliati M, et al. LRRK2 G2019S as a cause of Parkinson's disease in Ashkenazi Jews. N Engl J Med 2006; 354: 424–5.
Clark LN, Wang Y, Karlins E, Saito L, Mejia-Santana H, Harris J, et al. Frequency of LRRK2 mutations in early- and late-onset Parkinson disease. Neurology 2006; 67: 1786–91.
Orr-Urtreger A, Shifrin C, Rozovski U, Rosner S, Bercovich D, Gurevich T, et al. The LRRK2 G2019S mutation in Ashkenazi Jews with Parkinson's disease: is there a gender effect? Neurology 2007; 69: 1595–602.
Lesage S, Ibanez P, Lohmann E, Pollak P, Tison F, Tazir M, et al. G2019S LRRK2 mutation in French and North African families with Parkinson's disease. Ann Neurol 2005; 58: 784–7.
Lesage S, Durr A, Tazir M, Lohmann E, Leutenegger AL, Janin S, et al. LRRK2 G2019S as a cause of Parkinson's disease in North African Arabs. N Engl J Med 2006; 354: 422–3.
Di Fonzo A, Wu-Chou YH, Lu CS, van Doeselaar M, Simons EJ, Rohe CF, et al. A common missense variant in the LRRK2 gene, Gly2385Arg, associated with Parkinson's disease risk in Taiwan. Neurogenetics 2006; 7: 133–8.
Tan EK, Zhao Y, Skipper L, Tan MG, Di Fonzo A, Sun L, et al. The LRRK2 Gly2385Arg variant is associated with Parkinson's disease: genetic and functional evidence. Hum Genet 2007; 120: 857–63.
Fung HC, Chen CM, Hardy J, Singleton AB, Wu YR . A common genetic factor for Parkinson disease in ethnic Chinese population in Taiwan. BMC Neurol 2006; 6: 47.
Farrer MJ, Stone JT, Lin CH, Dachsel JC, Hulihan MM, Haugarvoll K, et al. Lrrk2 G2385R is an ancestral risk factor for Parkinson's disease in Asia. Parkinsonism Relat Disord 2007; 13: 89–92.
Funayama M, Li Y, Tomiyama H, Yoshino H, Imamichi Y, Yamamoto M, et al. Leucine-rich repeat kinase 2 G2385R variant is a risk factor for Parkinson disease in Asian population. Neuroreport 2007; 18: 273–5.
Aasly JO, Toft M, Fernandez-Mata I, Kachergus J, Hulihan M, White LR, et al. Clinical features of LRRK2-associated Parkinson's disease in central Norway. Ann Neurol 2005; 57: 762–5.
Wszolek ZK, Pfeiffer RF, Tsuboi Y, Uitti RJ, McComb RD, Stoessl AJ, et al. Autosomal dominant parkinsonism associated with variable synuclein and tau pathology. Neurology 2004; 62: 1619–22.
West AB, Moore DJ, Biskup S, Bugayenko A, Smith WW, Ross CA, et al. Parkinson's disease-associated mutations in leucine-rich repeat kinase 2 augment kinase activity. Proc Natl Acad Sci USA 2005; 102: 16842–7.
Kitada T, Asakawa S, Hattori N, Matsumine H, Yamamura Y, Minoshima S, et al. Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature 1998; 392: 605–8.
Valente EM, Abou-Sleiman PM, Caputo V, Muqit MM, Harvey K, Gispert S, et al. Hereditary early-onset Parkinson's disease caused by mutations in PINK1. Science 2004; 304: 1158–60.
Bonifati V, Rizzu P, van Baren MJ, Schaap O, Breedveld GJ, Krieger E, et al. Mutations in the DJ-1 gene associated with autosomal recessive early-onset parkinsonism. Science 2003; 299: 256–9.
Ramirez A, Heimbach A, Grundemann J, Stiller B, Hampshire D, Cid LP, et al. Hereditary parkinsonism with dementia is caused by mutations in ATP13A2, encoding a lysosomal type 5 P-type ATPase. Nat Genet 2006; 38: 1184–91.
Lucking CB, Durr A, Bonifati V, Vaughan J, De Michele G, Gasser T, et al. Association between early-onset Parkinson's disease and mutations in the parkin gene. N Engl J Med 2000; 342: 1560–7.
Mata IF, Lockhart PJ, Farrer MJ . Parkin genetics: one model for Parkinson's disease. Hum Mol Genet 2004; 13 Spec No 1: R127–33.
Klein C, Pramstaller PP, Kis B, Page CC, Kann M, Leung J, et al. Parkin deletions in a family with adult-onset, tremor-dominant parkinsonism: expanding the phenotype. Ann Neurol 2000; 48: 65–71.
Farrer M, Chan P, Chen R, Tan L, Lincoln S, Hernandez D, et al. Lewy bodies and parkinsonism in families with parkin mutations. Ann Neurol 2001; 50: 293–300.
Pramstaller PP, Schlossmacher MG, Jacques TS, Scaravilli F, Eskelson C, Pepivani I, et al. Lewy body Parkinson's disease in a large pedigree with 77 Parkin mutation carriers. Ann Neurol 2005; 58: 411–22.
Shimura H, Hattori N, Kubo S, Mizuno Y, Asakawa S, Minoshima S, et al. Familial Parkinson disease gene product, parkin, is a ubiquitin-protein ligase. Nat Genet 2000; 25: 302–5.
Valente EM, Bentivoglio AR, Dixon PH, Ferraris A, Ialongo T, Frontali M, et al. Localization of a novel locus for autosomal recessive early-onset parkinsonism, PARK6, on human chromosome 1p35-p36. Am J Hum Genet 2001; 68: 895–900.
Valente EM, Brancati F, Ferraris A, Graham EA, Davis MB, Breteler MM, et al. PARK6-linked parkinsonism occurs in several European families. Ann Neurol 2002; 51: 14–8.
Valente EM, Salvi S, Ialongo T, Marongiu R, Elia AE, Caputo V, et al. PINK1 mutations are associated with sporadic early-onset parkinsonism. Ann Neurol 2004; 56: 336–41.
Khan NL, Valente EM, Bentivoglio AR, Wood NW, Albanese A, Brooks DJ, et al. Clinical and subclinical dopaminergic dysfunction in PARK6-linked parkinsonism: an 18F-dopa PET study. Ann Neurol 2002; 52: 849–53.
Shen J, Cookson MR . Mitochondria and dopamine: new insights into recessive parkinsonism. Neuron 2004; 43: 301–4.
van Duijn CM, Dekker MC, Bonifati V, Galjaard RJ, Houwing-Duistermaat JJ, Snijders PJ, et al. Park7, a novel locus for autosomal recessive early-onset parkinsonism, on chromosome 1p36. Am J Hum Genet 2001; 69: 629–34.
Lockhart PJ, Lincoln S, Hulihan M, Kachergus J, Wilkes K, Bisceglio G, et al. DJ-1 mutations are a rare cause of recessively inherited early onset parkinsonism mediated by loss of protein function. J Med Genet 2004; 41: e22.
Dekker MC, Eshuis SA, Maguire RP, Veenmavan der Duijn L, Pruim J, Snijders PJ, et al. PET neuroimaging and mutations in the DJ-1 gene. J Neural Transm 2004; 111: 1575–81.
Canet-Aviles RM, Wilson MA, Miller DW, Ahmad R, McLendon C, Bandyopadhyay S, et al. The Parkinson's disease protein DJ-1 is neuroprotective due to cysteinesulfinic acid-driven mitochon-drial localization. Proc Natl Acad Sci USA 2004; 101: 9103–8.
Najimal-Din AS, Wriekat A, Mubaidin A, Dasouki M, Hiari M . Pallidopyramidal degeneration, supranuclear upgaze paresis and dementia: Kufor-Rakeb syndrome. Acta Neurol Scand 1994; 89: 347–52.
Hampshire DJ, Roberts E, Crow Y, Bond J, Mubaidin A, Wriekat AL, et al. Kufor-Rakeb syndrome, pallido-pyramidal degeneration with supranuclear upgaze paresis and dementia, maps to 1p36. J Med Genet 2001; 38: 680–2.
Di Fonzo A, Chien HF, Socal M, Giraudo S, Tassorelli C, Iliceto G, et al. ATP13A2 missense mutations in juvenile parkinsonism and young onset Parkinson disease. Neurology 2007; 68: 1557–62.
Jones JM, Datta P, Srinivasula SM, Ji W, Gupta S, Zhang Z, et al. Loss of Omi mitochondrial protease activity causes the neuro-muscular disorder of mnd2 mutant mice. Nature 2003; 425: 721–7.
Martins LM, Morrison A, Klupsch K, Fedele V, Moisoi N, Teismann P, et al. Neuroprotective role of the Reaper-related serine protease HtrA2/Omi revealed by targeted deletion in mice. Mol Cell Biol 2004; 24: 9848–62.
Strauss KM, Martins LM, Plun-Favreau H, Marx FP, Kautzmann S, Berg D, et al. Loss of function mutations in the gene encoding Omi/HtrA2 in Parkinson's disease. Hum Mol Genet 2005; 14: 2099–111.
Faccio L, Fusco C, Chen A, Martinotti S, Bonventre JV, Zervos AS . Characterization of a novel human serine protease that has extensive homology to bacterial heat shock endoprotease HtrA and is regulated by kidney ischemia. J Biol Chem 2000; 275: 2581–8.
Gray CW, Ward RV, Karran E, Turconi S, Rowles A, Viglienghi D, et al. Characterization of human HtrA2, a novel serine protease involved in the mammalian cellular stress response. Eur J Biochem 2000; 267: 5699–710.
Dawson TM, Dawson VL . Rare genetic mutations shed light on the pathogenesis of Parkinson disease. J Clin Invest 2003; 111: 145–51.
Schapira AH, Cooper JM, Dexter D, Jenner P, Clark JB, Marsden CD . Mitochondrial complex I deficiency in Parkinson's disease. Lancet 1989; 1: 1269.
Beal MF . Mitochondria, oxidative damage, and inflammation in Parkinson's disease. Ann N Y Acad Sci 2003; 991: 120–31.
Manning-Bog AB, McCormack AL, Li J, Uversky VN, Fink AL, Di Monte DA . The herbicide paraquat causes up-regulation and aggregation of alpha-synuclein in mice: paraquat and alpha-synuclein. J Biol Chem 2002; 277: 1641–4.
Sherer TB, Betarbet R, Testa CM, Seo BB, Richardson JR, Kim JH, et al. Mechanism of toxicity in rotenone models of Parkinson's disease. J Neurosci 2003; 23: 10756–64.
Moore DJ, West AB, Dawson VL, Dawson TM . Molecular patho-physiology of Parkinson's disease. Annu Rev Neurosci 2005; 28: 57–87.
Abou-Sleiman PM, Muqit MM, Wood NW . Expanding insights of mitochondrial dysfunction in Parkinson's disease. Nat Rev Neurosci 2006; 7: 207–19.
Webb JL, Ravikumar B, Atkins J, Skepper JN, Rubinsztein DC . Alpha-Synuclein is degraded by both autophagy and the proteasome. J Biol Chem 2003; 278: 25009–13.
Lee HJ, Khoshaghideh F, Patel S, Lee SJ . Clearance of alpha-synuclein oligomeric intermediates via the lysosomal degradation pathway. J Neurosci 2004; 24: 1888–96.
Cuervo AM, Stefanis L, Fredenburg R, Lansbury PT, Sulzer D . Impaired degradation of mutant alpha-synuclein by chaperone-mediated autophagy. Science 2004; 305: 1292–5.
Hruska KS, Goker-Alpan O, Sidransky E . Gaucher disease and the synucleinopathies. J Biomed Biotechnol 2006; 2006: 78549.
Tan EK, Khajavi M, Thornby JI, Nagamitsu S, Jankovic J, Ashizawa T . Variability and validity of polymorphism association studies in Parkinson's disease. Neurology 2000; 55: 533–8.
Gilgun-Sherki Y, Djaldetti R, Melamed E, Offen D . Polymorphism in candidate genes: implications for the risk and treatment of idiopathic Parkinson's disease. Pharmacogenomics J 2004; 4: 291–306.
Gandhi S, Abou-Sleiman PM, Healy DG, Weale M, Gilks W, Ahmadi K, et al. Population genetic approaches to neurological disease: Parkinson's disease as an example. Philos Trans R Soc Lond B Biol Sci 2005; 360: 1573–8.
Benmoyal-Segal L, Soreq H . Gene-environment interactions in sporadic Parkinson's disease. J Neurochem 2006; 97: 1740–55.
Neudorfer O, Giladi N, Elstein D, Abrahamov A, Turezkite T, Aghai E, et al. Occurrence of Parkinson's syndrome in type I Gaucher disease. QJM 1996; 89: 691–4.
Goker-Alpan O, Giasson BI, Eblan MJ, Nguyen J, Hurtig HI, Lee VM, et al. Glucocerebrosidase mutations are an important risk factor for Lewy body disorders. Neurology 2006; 67: 908–10.
Bertram L, McQueen MB, Mullin K, Blacker D, Tanzi RE . Systematic meta-analyses of Alzheimer disease genetic association studies: the AlzGene database. Nat Genet 2007; 39: 17–23.
Maraganore DM, de Andrade M, Lesnick TG, Strain KJ, Farrer MJ, Rocca WA, et al. High-resolution whole-genome association study of Parkinson disease. Am J Hum Genet 2005; 77: 685–93.
Elbaz A, Nelson LM, Payami H, Ioannidis JP, Fiske BK, Annesi G, et al. Lack of replication of thirteen single-nucleotide polymorphisms implicated in Parkinson's disease: a large-scale international study. Lancet Neurol 2006; 5: 917–23.
Fung HC, Scholz S, Matarin M, Simon-Sanchez J, Hernandez D, Britton A, et al. Genome-wide genotyping in Parkinson's disease and neurologically normal controls: first stage analysis and public release of data. Lancet Neurol 2006; 5: 911–6.
Evangelou E, Maraganore DM, Ioannidis JP . Meta-analysis in genome-wide association datasets: strategies and application in Parkinson disease. PLoS ONE 2007; 2: e196.
Langston JW, Ballard P, Tetrud JW, Irwin I . Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. Science 1983; 219: 979–80.
Betarbet R, Sherer TB, MacKenzie G, Garcia-Osuna M, Panov AV, Greenamyre JT . Chronic systemic pesticide exposure reproduces features of Parkinson's disease. Nat Neurosci 2000; 3: 1301–6.
Thiruchelvam M, Brockel BJ, Richfield EK, Baggs RB, Cory-Slechta DA . Potentiated and preferential effects of combined paraquat and maneb on nigrostriatal dopamine systems: environmental risk factors for Parkinson's disease? Brain Res 2000; 873: 225–34.
Priyadarshi A, Khuder SA, Schaub EA, Shrivastava S . A meta-analysis of Parkinson's disease and exposure to pesticides. Neurotoxicology 2000; 21: 435–40.
Liou HH, Tsai MC, Chen CJ, Jeng JS, Chang YC, Chen SY, et al. Environmental risk factors and Parkinson's disease: a case-control study in Taiwan. Neurology 1997; 48: 1583–8.
Lai BC, Marion SA, Teschke K, Tsui JK . Occupational and environmental risk factors for Parkinson's disease. Parkin-sonism Relat Disord 2002; 8: 297–309.
Elbaz A, Levecque C, Clavel J, Vidal JS, Richard F, Amouyel P, et al. CYP2D6 polymorphism, pesticide exposure, and Parkinson's disease. Ann Neurol 2004; 55: 430–4.
Menegon A, Board PG, Blackburn AC, Mellick GD, Le Couteur DG . Parkinson's disease, pesticides, and glutathione transferase polymorphisms. Lancet 1998; 352: 1344–6.
Kelada SN, Checkoway H, Kardia SL, Carlson CS, Costa-Mallen P, Eaton DL, et al. 5′ and 3′ region variability in the dopamine transporter gene (SLC6A3), pesticide exposure and Parkinson's disease risk: a hypothesis-generating study. Hum Mol Genet 2006; 15: 3055–62.
Dick F, De Palma G, Ahmadi A, Osborne A, Scott NW, Prescott GJ, et al. Gene-environment interactions in parkinsonism and Parkinson's disease: the Geoparkinson study. Occup Environ Med 2007.
Van Den Eeden SK, Tanner CM, Bernstein AL, Fross RD, Leimpeter A, Bloch DA, et al. Incidence of Parkinson's disease: variation by age, gender, and race/ethnicity. Am J Epidemiol 2003; 157: 1015–22.
Zhang ZX, Roman GC . Worldwide occurrence of Parkinson's disease: an updated review. Neuroepidemiology 1993; 12: 195–208.
Mellick GD, Buchanan DD, Silburn PA, Chan DK, Le Couteur DG, Law LK, et al. The monoamine oxidase B gene GT repeat polymorphism and Parkinson's disease in a Chinese population. J Neurol 2000; 247: 52–5.
Leighton PW, Le Couteur DG, Pang CC, McCann SJ, Chan D, Law LK, et al. The dopamine transporter gene and Parkinson's disease in a Chinese population. Neurology 1997; 49: 1577–9.
Chan DK, Mellick G, Cai H, Wang XL, Ng PW, Pang CP, et al. The alpha-synuclein gene and Parkinson disease in a Chinese population. Arch Neurol 2000; 57: 501–3.
Lesage S, Leutenegger AL, Ibanez P, Janin S, Lohmann E, Durr A, et al. LRRK2 haplotype analyses in European and North African families with Parkinson disease: a common founder for the G2019S mutation dating from the 13th century. Am J Hum Genet 2005; 77: 330–2.
Goldwurm S, Di Fonzo A, Simons EJ, Rohe CF, Zini M, Canesi M, et al. The G6055A (G2019S) mutation in LRRK2 is frequent in both early and late onset Parkinson's disease and originates from a common ancestor. J Med Genet 2005; 42: e65.
Zabetian CP, Hutter CM, Yearout D, Lopez AN, Factor SA, Griffith A, et al. LRRK2 G2019S in families with Parkinson disease who originated from Europe and the Middle East: evidence of two distinct founding events beginning two millennia ago. Am J Hum Genet 2006; 79: 752–8.
Lu CS, Simons EJ, Wu-Chou YH, Fonzo AD, Chang HC, Chen RS, et al. The LRRK2 I2012T, G2019S, and I2020T mutations are rare in Taiwanese patients with sporadic Parkinson's disease. Parkinsonism Relat Disord 2005; 11: 521–2.
Tan EK, Shen H, Tan LC, Farrer M, Yew K, Chua E, et al. The G2019S LRRK2 mutation is uncommon in an Asian cohort of Parkinson's disease patients. Neurosci Lett 2005; 384: 327–9.
Fung HC, Chen CM, Hardy J, Hernandez D, Singleton A, Wu YR . Lack of G2019S LRRK2 mutation in a cohort of Taiwanese with sporadic Parkinson's disease. Mov Disord 2006; 21: 880–1.
Di Fonzo A, Tassorelli C, De Mari M, Chien HF, Ferreira J, Rohe CF, et al. Comprehensive analysis of the LRRK2 gene in sixty families with Parkinson's disease. Eur J Hum Genet 2006; 14: 322–31.
Olanow CW, Watts RL, Koller WC . An algorithm (decision tree) for the management of Parkinson's disease (2001): treatment guidelines. Neurology 2001; 56: S1–S88.
Hughes AJ, Daniel SE, Kilford L, Lees AJ . Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 1992; 55: 181–4.
Olanow CW, Agid Y, Mizuno Y, Albanese A, Bonuccelli U, Damier P, et al. Levodopa in the treatment of Parkinson's disease: current controversies. Mov Disord 2004; 19: 997–1005.
Linazasoro G . New ideas on the origin of L-dopa-induced dyskinesias: age, genes and neural plasticity. Trends Pharmacol Sci 2005; 26: 391–7.
Weintraub D, Siderowf AD, Potenza MN, Goveas J, Morales KH, Duda JE, et al. Association of dopamine agonist use with impulse control disorders in Parkinson disease. Arch Neurol 2006; 63: 969–73.
Giladi N, Weitzman N, Schreiber S, Shabtai H, Peretz C . New-Onset Heightened Interest or Drive for Gambling, Eating, Shopping or Sexual Activity in Patients with Parkinson's Disease: The Role of Dopamine Agonist Treatment and Age at Motor Symptom Onset. J Psychopharmacology Apr 2007; 21: 501–6.
Ravina BM, Fagan SC, Hart RG, Hovinga CA, Murphy DD, Dawson TM, et al. Neuroprotective agents for clinical trials in Parkinson's disease: a systematic assessment. Neurology 2003; 60: 1234–40.
Olanow CW . The scientific basis for the current treatment of Parkinson's disease. Annu Rev Med 2004; 55: 41–60.
Fearnley JM, Lees AJ . Ageing and Parkinson's disease: substantia nigra regional selectivity. Brain 1991; 114 ( Pt 5): 2283–301.
Hudis CA . Trastuzumab—mechanism of action and use in clinical practice. N Engl J Med 2007; 357: 39–51.
Hu J, Zhou GB, Wang ZY, Chen SJ, Chen Z . Mutant transcription factors and tyrosine kinases as therapeutic targets for leukemias: from acute promyelocytic leukemia to chronic myeloid leukemia and beyond. Adv Cancer Res 2007; 98: 191–220.
Abeliovich A, Schmitz Y, Farinas I, Choi-Lundberg D, Ho WH, Castillo PE, et al. Mice lacking alpha-synuclein display functional deficits in the nigrostriatal dopamine system. Neuron 2000; 25: 239–52.
Dauer W, Kholodilov N, Vila M, Trillat AC, Goodchild R, Larsen KE, et al. Resistance of alpha -synuclein null mice to the parkinsonian neurotoxin MPTP. Proc Natl Acad Sci USA 2002; 99: 14524–9.
Fernagut PO, Chesselet MF . Alpha-synuclein and transgenic mouse models. Neurobiol Dis 2004; 17: 123–30.
Melrose HL, Lincoln SJ, Tyndall GM, Farrer MJ . Parkinson's disease: a rethink of rodent models. Exp Brain Res 2006; 173: 196–204.
McNaught KS, Olanow CW . Protein aggregation in the patho-genesis of familial and sporadic Parkinson's disease. Neurobiol Aging 2006; 27: 530–45.
Masliah E, Rockenstein E, Adame A, Alford M, Crews L, Hashimoto M, et al. Effects of alpha-synuclein immunization in a mouse model of Parkinson's disease. Neuron 2005; 46: 857–68.
Gloeckner CJ, Kinkl N, Schumacher A, Braun RJ, O'Neill E, Meitinger T, et al. The Parkinson disease causing LRRK2 mutation I2020T is associated with increased kinase activity. Hum Mol Genet 2006; 15: 223–32.
Greggio E, Jain S, Kingsbury A, Bandopadhyay R, Lewis P, Kaganovich A, et al. Kinase activity is required for the toxic effects of mutant LRRK2/dardarin. Neurobiol Dis 2006; 23: 329–41.
Hardy J, Cai H, Cookson MR, Gwinn-Hardy K, Singleton A . Genetics of Parkinson's disease and parkinsonism. Ann Neurol 2006; 60: 389–98.
Fleming SM, Fernagut PO, Chesselet MF . Genetic mouse models of parkinsonism: strengths and limitations. NeuroRx 2005; 2: 495–503.
Tan EK, Jankovic J . Genetic testing in Parkinson disease: promises and pitfalls. Arch Neurol 2006; 63: 1232–7.
Klein C, Schlossmacher MG . The genetics of Parkinson disease: Implications for neurological care. Nat Clin Pract Neurol 2006; 2: 136–46.
McInerney-Leo A, Hadley DW, Gwinn-Hardy K, Hardy J . Genetic testing in Parkinson's disease. Mov Disord 2005; 20: 1–10.
Klein C . Implications of genetics on the diagnosis and care of patients with Parkinson disease. Arch Neurol 2006; 63: 328–34.
Gasser T, Muller-Myhsok B, Wszolek ZK, Oehlmann R, Calne DB, Bonifati V, et al. A susceptibility locus for Parkinson's disease maps to chromosome 2p13. Nat Genet 1998; 18: 262–5.
Hicks AA, Petursson H, Jonsson T, Stefansson H, Johannsdottir HS, Sainz J, et al. A susceptibility gene for late-onset idiopathic Parkinson's disease. Ann Neurol 2002; 52: 549–55.
Pankratz N, Nichols WC, Uniacke SK, Halter C, Rudolph A, Shults C, et al. Significant linkage of Parkinson disease to chromosome 2q36-37. Am J Hum Genet 2003; 72: 1053–7.
Pankratz N, Nichols WC, Uniacke SK, Halter C, Murrell J, Rudolph A, et al. Genome-wide linkage analysis and evidence of gene-by-gene interactions in a sample of 362 multiplex Parkinson disease families. Hum Mol Genet 2003; 12: 2599–608.
Author information
Authors and Affiliations
Corresponding author
Additional information
Project supported by funds from the MK Humanitarian Fund, National Parkinson Foundation (Miami, USA), Tel-Aviv Sourasky Medical Center Grant of Excellence, and the Wolfson Foundation.
Rights and permissions
About this article
Cite this article
Rosner, S., Giladi, N. & Orr-Urtreger, A. Advances in the genetics of Parkinson's disease. Acta Pharmacol Sin 29, 21–34 (2008). https://doi.org/10.1111/j.1745-7254.2008.00731.x
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1111/j.1745-7254.2008.00731.x
Keywords
This article is cited by
-
The Synergistic Effect Study of Lipopolysaccharide (LPS) and A53T-α-Synuclein: Intranasal LPS Exposure on the A53T-α-Synuclein Transgenic Mouse Model of Parkinson’s Disease
Molecular Neurobiology (2024)
-
A sporadic Parkinson’s disease model via silencing of the ubiquitin–proteasome/E3 ligase component, SKP1A
Journal of Neural Transmission (2023)
-
Autoimmunity, dendritic cells and relevance for Parkinson’s disease
Journal of Neural Transmission (2013)
-
Biomarkers for prediction and targeted prevention of Alzheimer’s and Parkinson’s diseases: evaluation of drug clinical efficacy
EPMA Journal (2010)